To test these hypotheses, we first performed VASP immunohistochemistry (IHC) and Kaplan–Meier survival analysis for patient samples and found that VASP was upregulated in the majority of colorectal cancers (CRCs) and pancreatic ductal adenocarcinomas (PDACs) and that high VASP levels correlated with liver metastasis and reduced patient survival. The gene discussed is VASP; the disease is pancreatic ductal adenocarcinoma.